Director at Guardant Health (GH) receives 232 shares via RSUs

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Guardant Health director Manuel Hidalgo Medina exercised restricted stock units into common shares as part of his equity compensation. On March 17, 2026, 232 restricted stock units converted into 232 shares of common stock at a stated price of $0.00 per share, raising his direct common stock holdings to 1,425 shares. The award originated from a grant on July 17, 2024 that vests over four years, with 25% vesting on the one-year anniversary and the remaining 75% vesting monthly over the following three years.

Insider Trade Summary

232 shares exercised/converted

Mixed 2 txns

Insider Hidalgo Medina Manuel

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	232	$0.00	--
Exercise	Common Stock	232	$0.00	--

Holdings After Transaction: Restricted Stock Units — 6,497 shares (Direct); Common Stock — 1,425 shares (Direct)

Footnotes (1)

The restricted stock unit award granted on July 17, 2024 vests over a four-year period. 25% of the shares subject to such award vested on the one-year anniversary of July 17, 2024 and the remaining 75% vests monthly for the three-year period thereafter. Not applicable for Restricted Stock Units.

Form 4 Insider Transactions: What Each Field Means →

03/18/2026 - 05:40 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hidalgo Medina Manuel

(Last)

(First)

(Middle)

3100 HANOVER STREET

(Street)

PALO ALTO

CALIFORNIA

94304

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/17/2026		M		232	A	$0	1,425	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	$0	03/17/2026		M			232	⁽¹⁾	⁽²⁾	Common Stock	232	$0	6,497	D

Explanation of Responses:

1. The restricted stock unit award granted on July 17, 2024 vests over a four-year period. 25% of the shares subject to such award vested on the one-year anniversary of July 17, 2024 and the remaining 75% vests monthly for the three-year period thereafter.

2. Not applicable for Restricted Stock Units.

Remarks:

	/s/ John G. Saia, as attorney-in-fact for Manuel Hidalgo Medina	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Guardant Health (GH) report for Manuel Hidalgo Medina?

Guardant Health reported that director Manuel Hidalgo Medina exercised 232 restricted stock units into 232 common shares. The transaction occurred on March 17, 2026, at a stated price of $0.00 per share and reflects routine vesting of equity compensation.

How many Guardant Health (GH) shares does Manuel Hidalgo Medina hold after this Form 4?

After the transaction, Manuel Hidalgo Medina directly holds 1,425 shares of Guardant Health common stock. This position reflects the conversion of 232 restricted stock units into common shares on March 17, 2026, as part of his ongoing director equity compensation program.

What type of securities were involved in Manuel Hidalgo Medina’s Guardant Health Form 4?

The Form 4 shows an exercise of restricted stock units that settled in Guardant Health common stock. Specifically, 232 restricted stock units converted into 232 common shares at a stated price of $0.00 per share, consistent with standard equity award vesting mechanics.

When do Manuel Hidalgo Medina’s Guardant Health restricted stock units vest?

The restricted stock unit award granted on July 17, 2024 vests over four years. Twenty-five percent vests on the one-year anniversary of July 17, 2024, and the remaining 75% vests in equal monthly installments over the following three-year period, subject to continued service.

Was Manuel Hidalgo Medina’s Guardant Health Form 4 transaction an open-market purchase or sale?

The reported transaction was an exercise of restricted stock units, not an open-market trade. The units converted into 232 common shares at a stated price of $0.00 per share, reflecting compensation-related vesting rather than discretionary buying or selling in the market.